FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/12/2026
Back to search
Official data from USPTO
ANGICYTE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ANGICYTE
ST13
US500000079399244Class
1, 5, 10, 42, 44
Filing
79399244
Registration
7838997
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
04/03/2026
Trademark type
Word
Nice classes
1, 5, 10, 42, 44
Filing date
03/04/2024
Registration date
06/24/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/24/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
24
Owner location
GB
Examiner
JANSON, ANDREW KYLE
Law office
L50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
VASCVERSA LIMITED
Representatives
Usha Menon D'Ambrosio & Menon, PLLC
Technical classification
Nice Classes
Class 1Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Stem cells for research purposes; stem cells for scientific purposes; chemicals for use in manufacturing pharmaceuticals; reagents for research purposes; reagents for medical research; reagents for scientific purposes; diagnostic reagents for scientific or research use; cell culture reagents for scientific and research use; blood culture media for scientific use
Class 5
Pharmaceutical preparations for the treatment of ischemic diseases; Drugs for medical purposespharmaceutical preparations for the treatment of ischemic diseases; Pharmaceutical preparations containing stem cells for the treatment of ischemic diseases and stimulation of vascular regenerationblood vessel repairtissue revitalization; Stem cells for medical purposes; cells for medical use; cell growth media for growing cells for medical use; living cells for medical use; cellular function activating agents for medical purposes; Vaccines; Reagents for medical use; medical diagnostic reagents
Class 10
Medical devices for the treatment of ischemic diseases and stimulation of vascular regenerationblood vessel repairtissue revitalization; Medical apparatus and instruments for the treatment of ischemic diseases and stimulation of vascular regenerationblood vessel repairtissue revitalization; Apparatus for the regeneration of stem cells for medical purposes; medical devices and apparatus for vascular regeneration and repair in the treatment of ischemic diseases; Medical devices and apparatus for cell therapy for the treatment of ischemic diseases and stimulation of vascular regenerationblood vessel repairtissue revitalization; Blood testing apparatus
Class 42
Medical and pharmacological research services; Stem cell research; Scientific research services for others relating to the isolation and cultivation of human tissues and cells; Research in the field of cell engineering technology; Scientific and medical research in the field of vascular regeneration and repair; Research and development of medicines; Pharmaceutical drug development services; Drug discovery services; Development of pharmaceutical preparations and medicines; Development of stem and progenitor cell therapies and other cell therapies; Research and development services in the medical field of cell therapy; research and development services in the medical field of vascular regeneration and repair; Scientific research in the nature of conducting clinical trials for others; Blood analysis services for scientific research purposes
Class 44
Regenerative medicine services; medical services; stem cell therapy services; cell therapy services; Stem cell therapy services for vascular regeneration and repair; cell therapy services relating to the generation of human vascular reparative cells; cell therapy services relating to the injectinggrafting or implanting of cells into patients; medical services relating to the removaltreatment and processing of cells; Medical services relating to the removaltreatment and processing of stem cells; Stem cell storagestem cell bank services; Cultured cell bank services for medical transplantation; medical laboratory services for the analysis of samples taken from patients; Medical analysis services for the diagnosis and treatment of persons; Services for the testing of bloodmedical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical services relating to the removaltreatment and processing of human blood
Publications
History of USPTO decisions and trademark events.
28 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/19/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/05/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/21/2026
FIMP
FINAL DISPOSITION PROCESSED
01/21/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/18/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/03/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/03/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/24/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/11/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/24/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
06/24/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/06/2025
PUBO
PUBLISHED FOR OPPOSITION
05/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/30/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/07/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/13/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/13/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/13/2025
RFNT
REFUSAL PROCESSED BY IB
10/12/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/21/2024
RFRR
REFUSAL PROCESSED BY MPU
09/20/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/19/2024
CNRT
NON-FINAL ACTION WRITTEN
09/18/2024
DOCK
ASSIGNED TO EXAMINER
09/18/2024
MAFR
APPLICATION FILING RECEIPT MAILED
07/11/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/11/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/04/2024
Continuous trademark protection
Get notified about every new filing that threatens ANGICYTE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.